The University of Chicago Header Logo

Connection

Richard A. Larson to Immunotherapy

This is a "connection" page, showing publications Richard A. Larson has written about Immunotherapy.
Connection Strength

0.934
  1. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv. 2018 07 24; 2(14):1705-1718.
    View in: PubMed
    Score: 0.424
  2. Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma. Curr Hematol Malig Rep. 2023 12; 18(6):217-225.
    View in: PubMed
    Score: 0.150
  3. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med. 2018 12 27; 379(26):2517-2528.
    View in: PubMed
    Score: 0.109
  4. Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. Blood. 2011 Jun 30; 117(26):7007-13.
    View in: PubMed
    Score: 0.064
  5. Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. Leuk Lymphoma. 2009 Jan; 50(1):85-91.
    View in: PubMed
    Score: 0.055
  6. Adult ALL: where are we and where are we going? Clin Adv Hematol Oncol. 2004 Jun; 2(6):342-4.
    View in: PubMed
    Score: 0.040
  7. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005 Jan 01; 105(1):49-53.
    View in: PubMed
    Score: 0.040
  8. miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib. Leukemia. 2015 May; 29(5):1210-3.
    View in: PubMed
    Score: 0.021
  9. Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies. J Clin Oncol. 2013 Feb 01; 31(4):440-7.
    View in: PubMed
    Score: 0.018
  10. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. J Clin Oncol. 2008 Oct 20; 26(30):4934-9.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.